Glaxo Buys Full Control of Consumer JV From Novartis, Strengthening Cash Flows for the Dividend
Glaxo’s acquisition of the Novartis portion in its consumer healthcare joint venture should strengthen Glaxo’s cash flow generation and further support its dividend, but we don’t expect any major impacts to the fair value estimates for either company. With the acquisition, Glaxo further entrenches itself in the consumer healthcare market (taking full ownership of the joint venture, up from the current 63.5% stake). With Glaxo’s further entrenchment in consumer healthcare, we expect the brand pow...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.